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Genetics and pharmacology can elicit surprisingly different phenotypes despite targeting 
the same protein. This Essay explores these unexpected differences and their implications 
for biology and medicine.Introduction
Genetics and pharmacology are the 
two dominant approaches for prob-
ing protein function in cells. In many 
cases, however, a small molecule and 
a genetic mutation can perturb a pro-
tein’s activity in different ways, lead-
ing to different conclusions about the 
protein’s biological function.
For example, the thiazolidinedi-
ones (TZDs) are widely prescribed 
drugs for the treatment of type II 
diabetes. TZDs were originally dis-
covered based on their ability to 
enhance insulin sensitivity in obese 
rats (Kobayashi et al., 1983), but 
their molecular targets remained 
elusive. In 1995, these compounds 
were shown to be selective ago-
nists of PPARγ, a nuclear hormone 
receptor that is a master regulator 
of adipogenesis (Lehmann et al., 
1995). The identification of PPARγ 
as the target of TZDs was counter-
intuitive: these drugs are used to 
treat diabetes, a disease caused by 
obesity, yet activate PPARγ, a tran-
scription factor that promotes adi-
pogenesis. Heterozygous deletion 
of the PPARγ gene, in fact, improves 
insulin sensitivity in mice (Kubota et 
al., 1999), suggesting that PPARγ 
inhibitors, rather than activators, 
should be developed as antidiabetic 
drugs. This paradox was ultimately 
resolved by showing that genetic 
antagonism and pharmacological 
agonism of PPARγ both improve glu-
cose metabolism but do so through 
different mechanisms (Yamauchi et 
al., 2001). In the case of TZD drugs, enhanced insulin sensitivity in the 
liver and muscle is achieved at the 
expense of increased adipose tis-
sue and weight gain.
In this example, TZDs revealed a 
therapeutic potential of PPARγ ago-
nists that was not predicted from 
genetic analysis. How often do small 
molecules reveal unexpected prop-
erties of their biological target? This 
question has not been explored 
systematically, in part because the 
selectivity of many pharmacologi-
cal agents is unknown and difficult 
to assess. Indeed, less than 5% of 
the proteome is currently targeted by 
a potent small molecule; it remains 
laborious and expensive to identify 
a single new compound with useful 
selectivity; and there is no general 
strategy to inventory the cellular tar-
gets of any molecule. By contrast, 
modern genetic approaches make 
it possible to link genes to pheno-
types efficiently, using robust tools 
that are widely accessible to the 
research community. What is the 
role of pharmacology in a biological 
universe dominated by the power of 
genetics?
Here, we highlight recent experi-
ments in which a small molecule 
and a mutation targeting the same 
protein have produced radically dif-
ferent phenotypes. Through these 
examples, we describe the mecha-
nisms by which pharmacology and 
genetics perturb biological systems 
in different ways and therefore pro-
vide different information about 
their targets.Cell 128, FTransferring Genetic Selectivity 
to a Small Molecule
A critical feature of a genetic screen 
is that it is possible to identify unam-
biguously the mutation that is respon-
sible for producing a phenotype. By 
contrast, there is no way to compre-
hensively identify the cellular targets 
of a small molecule. This ambigu-
ity confounds direct comparisons 
between genetic and pharmacologi-
cal phenotypes because it is always 
possible that any difference reflects 
an off-target effect of the drug.
One way to overcome this difficulty 
is to use a mutation to confer selectiv-
ity on a small molecule, an approach 
referred to as chemical genetics (we 
use the term chemical genetics in 
this restricted sense to distinguish it 
from pharmacology). For the protein 
kinase superfamily, a single residue 
in the ATP-binding pocket, termed 
the gatekeeper, has been shown to 
control sensitivity to a wide range of 
small molecule inhibitors (Bishop et 
al., 2000b). This gatekeeper residue 
is conserved as a large hydrophobic 
amino acid among protein kinases, 
but mutation of the gatekeeper to 
alanine or glycine creates a novel 
pocket that can be uniquely accessed 
by an inhibitor analog (Figure 1A). This 
inhibitor analog does not inhibit any 
wild-type kinase, and the gatekeeper 
mutation typically does not impair the 
mutated kinase. In this way, the effects 
of selective pharmacological inhibition 
of a kinase can be explored in a model 
system in which the wild-type kinase 
has been replaced with the drug-sen-ebruary 9, 2007 ©2007 Elsevier Inc. 425
Figure 1. Mechanism of Action of Small Molecule Inhibitors
(A) Mutation of the gatekeeper residue in a protein kinase creates a new pocket (red) that can be uniquely accessed by the small-molecule inhibitor 
analog 1NM-PP1. 
(B) Inhibition of a drug-sensitized yeast cyclin-dependent kinase Cdc28 with a low dose of 1NM-PP1 (0.5 µM) induces cell-cycle arrest at G2/M, 
whereas a higher dose of 1NM-PP1 (5 µM) induces cell-cycle arrest in G1. Mutant yeast with temperature-sensitive Cdc28 alleles also arrest in G1. 
(C) An increase in the sensitivity of the human epidermal growth factor receptor HER3 to phosphorylation by HER2 (for example, by downregula-
tion of a HER3 phosphatase) can induce resistance to small-molecule inhibitors targeting the kinase domains of EGFR/HER2, even though these 
compounds still bind to the receptors. Reversible inhibitors, irreversible inhibitors, and gene knockouts differ quantitatively in their ability to inhibit 
the kinase domains of EGFR/HER2, and this is reflected in the differing drug resistance phenotypes observed. 
(D) Accumulation of unfolded proteins in the lumen of the endoplasmic reticulum induces the Ire1 transmembrane kinase to dimerize (left). The Ire1 
dimer then becomes autophosphorylated resulting in activation of its RNase domain, thereby triggering the unfolded protein response. An Ire1 ki-
nase-dead allele cannot activate its RNase domain and so the unfolded protein response cannot be triggered. The ATP competitive kinase inhibitor 
1NM-PP1 rescues the ability of kinase-dead Ire1 to activate its RNase domain such that the unfolded protein response is triggered despite an Ire1 
that lacks kinase activity (right).
(E) p110γ allosterically activates PDE3B (the enzyme that catalyzes cAMP destruction) independent of its kinase activity through the p87 adaptor 
protein. Small-molecule inhibitors of p110γ block kinase activity but do not affect cAMP production, whereas knockout of the p110γ gene results in 
loss of kinase activity and altered cAMP production.sitive allele. A similar approach has 
been used to identify allele-specific 
ligands for proteins from several fami-
lies, including GTPases, G protein-
coupled receptors, nuclear hormone 
receptors, motor proteins, and phos-
phatases (Bishop et al., 2000a). For 
each of these proteins, a small mol-
ecule binding site was reengineered 
to bind uniquely to a synthetic ligand. 
As a result, it is possible to perform 
a critical control experiment in which 
target-less wild-type cells are treated 
with the synthetic ligand and thereby 
confirm that any phenotype requires 
the drug’s target. Here, we focus on 
how this approach has been used 
alongside traditional pharmacol-
ogy to explore cases in which kinase 
inhibitors and knockouts have pro-
duced different functional outcomes 
(Table 1).426 Cell 128, February 9, 2007 ©2007 ElsGraded Inhibition and  
Intermediate Phenotypes
An early application of chemical genet-
ics explored the role of the yeast cyc-
lin-dependent kinase Cdc28 in control-
ling progression through the cell cycle 
(Bishop et al., 2000b). Chemical inhibi-
tion of a drug-sensitized Cdc28 allele 
with the inhibitor analog 1NM-PP1 (0.5 
µM) induced specific cell-cycle arrest 
resulting in large hyperpolarized yeast 
buds and replicated DNA, indicative of 
failure to enter mitosis (Figure 1B). DNA 
microarray analysis confirmed that 
inhibition of Cdc28 blocked expres-
sion of key proteins required for the 
G2/M transition. Treatment of wild-
type yeast with 1NM-PP1 had no effect 
on their morphology, proliferation, or 
gene expression profile, confirming the 
selectivity of 1NM-PP1 for the drug-
sensitized Cdc28.evier Inc.The G2/M arrest induced by phar-
macological inhibition of Cdc28 con-
tradicts earlier studies using tem-
perature-sensitive yeast mutants, 
which resulted in arrest of unbudded 
cells in G1 (Figure 1B). Bishop et al. 
hypothesized that this discrepancy 
might reflect a quantitative differ-
ence in the level of Cdc28 activity 
required to drive specific cell-cycle 
transitions. In this model, entry into 
mitosis requires a high level of Cdc28 
activity and therefore is sensitive to 
low concentrations of drug, whereas 
progress through S phase requires 
less Cdc28 activity and therefore is 
sensitive only to high drug concen-
trations or genetic ablation of the 
protein. To test this hypothesis, the 
drug-sensitive Cdc28 strain was syn-
chronized by treatment with α factor 
and then the yeast were released 
Table 1. Phenotypic Differences between Kinase Inhibitors and Knockout Models
Kinase Knockout Phenotype Inhibition Phenotype Proposed Explanation Class
CDC28 Temperature-sensitive al-
leles arrest in G1 at restric-
tive temperature
Chemical inhibition induces 
G2/M arrest (low doses) and 
G1 arrest (high doses)
The mitotic checkpoint is more sensitive 
to cyclin-dependent kinase activity than 
the G1 checkpoint
Phenotypic 
threshold
Ire1 Knockout of Ire1 or ex-
pression of a kinase-dead 
allele blocks the unfolded 
protein response (UPR)
An ATP competitive inhibitor of 
the kinase-dead allele rescues 
the UPR
An ATP competitive ligand for the Ire1 
kinase domain allosterically activates 
the Ire1 RNAse domain during the UPR
Allosteric drug
Apg1 Cells lacking Apg1 are 
defective in cytoplasm-to-
vacuole targeting (Cvt) and 
autophagy
Chemical inhibition or expres-
sion of Apg1-kinase dead 
blocks Cvt but not autophagy
Cvt requires catalytic activity of Apg1, 
whereas autophagy requires its scaf-
folding function
Disrupted 
 protein 
 complex
Cla4 Cells lacking Cla4 are 
defective in septin localiza-
tion 
Chemical inhibition has no ef-
fect on septin localization
Septin localization may depend on a 
scaffolding function of Cla4
Disrupted 
 protein 
 complex
Elm1 Cells lacking Elm1 undergo 
G2/M delay
Chemical inhibition causes 
G1 delay in bud emergence 
and Cln2 synthesis, as well as 
defective G2/M 
Elm1 knockout cells accumulate sup-
pressors during culture that compen-
sate for the G1 defect
Cellular 
 compensation
JNK2 JNK2 knockout cells have 
normal c-Jun phos-
phorylation and increased 
proliferation
Chemical inhibition of JNK2 
blocks c-Jun phosphorylation 
and cellular proliferation
Jnk2 knockout causes a compensa-
tory increase in Jnk1 activity and c-Jun 
expression
Cellular 
 compensation
Aurora 
B
RNAi targeting impairs 
cell-cycle arrest in re-
sponse to both Taxol and 
Nocodazole 
The ZM-447439 inhibitor 
impairs checkpoint arrest in 
response to Taxol, but not 
Nocodazole
RNAi targeting of Aurora B disrupts a 
centromeric complex, yielding a more 
severe phenotype than chemical inhibi-
tion
Disrupted 
 protein 
 complex
EGFR RNAi targeting kills tumor 
cell lines resistant to the 
EGFR inhibitor gefitinib
Gefitinib cannot kill resistant 
tumor cells, even though they 
lack EGFR mutations that 
block gefitinib binding
Drug resistance is associated with 
changes that amplify low-level EGFR 
activity
Phenotypic 
threshold
p110γ Knockout mice show in-
creased cardiac contractil-
ity and tissue damage
Mice expressing the kinase-
dead allele have normal 
cardiac function
p110γ allosterically activates PDE3B, 
thereby regulating heart contractility 
independent of kinase activity
Disrupted 
 protein 
 complex
p110α Heterozygous knockout 
mice have normal insulin 
signaling (homozygous 
knockout is not viable)
Heterozygous mice express-
ing the kinase-dead allele or 
treated with a p110α inhibitor 
have impaired insulin signaling
Reduced expression of p110α in the 
knockout triggers compensation, partly 
by altering its stoichiometry relative to 
p85
Disrupted 
 protein 
 complex 
mTOR RNAi targeting blocks 
phosphorylation of Akt at 
Ser473 in most cell types
The inhibitor rapamycin in-
creases phosphorylation of Akt 
at Ser473 in most cell types
mTOR-rictor is insensitive to rapamycin 
and phosphorylates Akt.  mTOR-raptor 
is sensitive to rapamycin and controls 
a negative feedback loop inhibiting Akt 
phosphorylation.
Allosteric drug, 
 disrupted 
 protein 
 complexfrom cell-cycle arrest in the presence 
of a higher concentration of 1NM-
PP1 (5 µM). Under these conditions, 
inhibition of Cdc28 induced a uniform 
G1 arrest in which cells formed small 
buds but failed to undergo DNA rep-
lication (Figure 1B). Thus, complete 
Cdc28 inhibition induces primary 
arrest in G1, whereas partial Cdc28 
inhibition causes secondary arrest 
at G2/M. This graded response to 
pharmacological inhibition is con-
sistent with quantitative models of the cell cycle that suggest that entry 
into mitosis requires enhanced cyc-
lin-dependent kinase activity (Stern 
and Nurse, 1996).
The G2/M arrest after partial Cdc28 
inhibition represents an intermediate 
phenotype that was revealed by dos-
ing with a small molecule inhibitor but 
masked by genetic approaches that 
resulted in total loss of protein func-
tion (such as knockout of the Cdc28 
gene). Such quantitative differences 
in target inhibition can be critical Cell 128, Fedeterminants of the clinical efficacy 
of a small molecule. For example, 
gefitinib is a small molecule inhibi-
tor of the tyrosine kinase domain of 
the epidermal growth factor recep-
tor (EGFR; also called HER1) that 
has been used clinically to treat 
various tumors including breast can-
cer and non-small cell lung cancer. 
In many cancer patients, the initial 
response to this drug is followed by 
drug resistance and disease progres-
sion. However, drug resistance is not bruary 9, 2007 ©2007 Elsevier Inc. 427
always associated with mutations 
in the kinase domain of EGFR that 
block binding of the drug, and tumor 
cell lines selected in vitro for resist-
ance to gefitinib often do not acquire 
EGFR mutations (Kwak et al., 2005). 
Nonetheless, these gefitinib-resist-
ant tumor cells remain sensitive to 
genetic blockade of EGFR signaling 
(that is, they can be killed by small 
interfering RNAs that target EGFR or 
its binding partner HER2). What is the 
reason for this? Gefitinib resistance 
is associated with downregulation of 
cellular tyrosine phosphatase activity 
and increased expression of EGFR/
HER2 substrates, two mechanisms 
that amplify the EGFR-depend-
ent substrate phosphorylation that 
remains after drug treatment (Ser-
gina et al., 2007). This suggests that 
tumor cells can become resistant to 
gefitinib by increasing their thresh-
old for EGFR inhibition (Figure 1C) 
without specifically preventing the 
drug’s mechanism of action by, for 
example, acquiring EGFR mutations 
that block drug binding. Consistent 
with this model, gefitinib-resistant 
cancer cells remain sensitive to irre-
versible EGFR inhibitors, molecules 
that are structural analogs of gefit-
inib but that are more potent due to 
their covalent mechanism of action 
(Kwak et al., 2005). Thus, tumor cells 
can achieve resistance to a kinase 
inhibitor, despite retaining a genetic 
requirement for its target, by exploit-
ing quantitative differences in target 
inhibition.
Allosteric Mechanisms of Small 
Molecule Action
Ire1 is an endoplasmic reticulum 
transmembrane kinase that con-
trols the unfolded protein response, 
the process by which accumulation 
of unfolded proteins in the lumen 
of the endoplasmic reticulum acti-
vates production of chaperones 
and related proteins (Patil and 
Walter, 2001). Unfolded proteins in 
the endoplasmic reticulum induce 
dimerization of Ire1, resulting in acti-
vation of the Ire1 kinase domains 
and RNase domains and initiation of 
the unfolded protein response (Fig-
ure 1D). Mutations that disable the 428 Cell 128, February 9, 2007 ©2007 EIre1 kinase are known to block the 
unfolded protein response, but the 
biochemical function of this kinase 
has been poorly understood, as it 
has no known protein substrates.
To investigate signaling by Ire1, 
wild-type Ire1 kinase was replaced 
with a drug-sensitive mutant (L745G) 
(Papa et al., 2003). In this case, the 
drug-sensitizing mutation mark-
edly impaired Ire1 kinase activity 
and activation of the unfolded pro-
tein response. Paradoxically, when 
cells expressing the weakened Ire1 
(L745G) allele were treated with the 
inhibitor 1NM-PP1, there was almost 
complete recovery of the ability of 
Ire1 (L745G) to induce the unfolded 
protein response.
How is this possible? Control 
experiments confirmed that 1NM-
PP1 rescued the unfolded protein 
response through a direct and spe-
cific interaction with Ire1(L745G). 
To explain this, the authors hypoth-
esized that the Ire1 kinase domain 
allosterically activates the Ire1 RNase 
domain, which is sufficient to trigger 
the unfolded protein response, and 
that this conformational signal is con-
trolled by nucleotide binding to the 
kinase. In this model, binding of 1NM-
PP1 to the Ire1(L745G) kinase mimics 
nucleotide-dependent allosteric acti-
vation of the RNase domain resulting 
in rescue of Ire1 function (Figure 1D).
This hypothesis was tested by 
constructing a double mutant form 
of Ire1(L745G/D828A) that combines 
kinase-dead and drug-sensitiz-
ing mutations. This double mutant 
had no detectable kinase activity 
but was able to bind to the kinase 
inhibitor 1NM-PP1. Yeast express-
ing Ire1(L745G/D828A) failed to trig-
ger the unfolded protein response in 
the absence of drug but were able to 
induce the unfolded protein response 
to near wild-type levels in the pres-
ence of 1NM-PP1 (Figure 1D). Thus, 
1NM-PP1 acts as an Ire1 agonist 
rather than an Ire1 inhibitor, even 
though this compound binds to the 
Ire1 active site and directly blocks its 
kinase activity.
In this case, a kinase inhibitor 
rescued the phenotype of a kinase-
dead mutation, revealing a signaling lsevier Inc.mechanism in which Ire1 shuttles 
between active and inactive confor-
mations in response to ligand binding 
at the ATP site. Is Ire1 unique or do 
other kinases signal in this way? No 
functional protein kinase is known to 
signal in this manner, but the enzyme 
RNase L contains a kinase domain 
that lacks essential catalytic resi-
dues (referred to as a pseudokinase 
domain), and binding of nucleotides 
to this pseudokinase regulates its 
RNase activity (Dong and Silverman, 
1999). The human genome encodes 
at least 48 pseudokinases, and 
many of these proteins regulate key 
signaling pathways or are the target 
of amplification and mutation in can-
cer (Boudeau et al., 2006). The bio-
chemical mechanisms that mediate 
pseudokinase signaling are largely 
unknown, but it is likely that many 
use allosteric mechanisms similar to 
Ire1. Thus, it may be possible to acti-
vate or inhibit these pseudokinases 
by developing drugs that target their 
vestigial active sites.
Inhibiting Kinase Activity but 
Leaving Protein Complexes Intact
Small molecules typically do not alter 
the expression of their target protein. 
In contrast, knockout of a gene results 
in complete loss of the target protein, 
which can disrupt protein complexes 
or impair functional domains that 
would be unaffected by a drug. These 
secondary effects can dominate the 
phenotype of a knockout, such that 
a knockout and a small molecule 
inhibitor targeting the same protein 
produce very different outcomes.
Studies of the PI3-kinase p110γ 
illustrate how disruption of a pro-
tein complex through knockout of a 
gene encoding one of the complex 
subunits can induce a more severe 
phenotype than the corresponding 
small molecule inhibitor. p110γ medi-
ates the response of leukocytes to 
diverse chemotactic and inflamma-
tory stimuli, and mice that lack p110γ 
have a dampened immune response 
(Hirsch et al., 2000; Sasaki et al., 
2000). This finding has generated 
significant interest in p110γ inhibitors 
as anti-inflammatory drugs. How-
ever, analysis of p110γ knockout mice 
revealed that these animals exhibit 
elevated contractility of cardiac mus-
cle (Crackower et al., 2002) and suffer 
from myocardial damage in response 
to aortic constriction (Patrucco et al., 
2004). The cardiac phenotype of the 
p110γ knockout animals was surpris-
ing, in part because overexpression 
of a kinase-dead p110γ in heart mus-
cle protects mice from myocardial 
damage (Nienaber et al., 2003). Why 
does deletion of p110γ produce a 
phenotype opposite to that obtained 
by overexpression of a kinase-dead 
allele? The increased cardiac con-
tractility in the p110γ knockout mice 
is associated with increased cAMP 
in cardiomyocytes, suggesting that 
p110γ may regulate cAMP levels. To 
address this possibility, Patrucco et 
al. (2004) generated knockin mice that 
express a p110γ kinase-dead allele at 
wild-type levels from the endogenous 
locus. These animals, which better 
mimic the effects of a small molecule 
inhibitor, retain the immune deficits 
of the original p110γ knockout mice 
but have normal heart tissue, indicat-
ing that the cardiac defect is not due 
to loss of p110γ kinase activity. Fur-
ther investigation revealed that p110γ 
binds to and allosterically activates 
PDE3B, the enzyme that catalyzes 
cAMP destruction (Patrucco et al., 
2004). Deletion of the gene encod-
ing p110γ disrupts this critical pro-
tein-protein interaction, leading to 
pathological accumulation of cAMP 
and cardiac failure (Figure 1E). As 
the regulation of PDE3B by p110γ is 
independent of kinase activity, it is 
unaffected by small molecule kinase 
inhibitors targeting p110γ (Patrucco 
et al., 2004).
Similar effects have been observed 
for inhibitors of Aurora kinases. These 
kinases monitor spindle assembly 
and chromosome alignment during 
mitosis, triggering checkpoints that 
ensure proper chromosome segre-
gation and cytokinesis. Many tumors 
overexpress Aurora kinases, sparking 
interest in these enzymes as potential 
cancer drug targets. Knockdown of 
Aurora B by RNA interference (RNAi) 
induces a range of mitotic defects, 
including failure of cells to arrest in 
response to paclitaxel (a microtubule-stabilizing agent) or nocodazole (a 
microtubule polymerization inhibitor) 
and failure of microtubules to become 
properly attached to kinetochores, 
leading to chromosome mislocaliza-
tion (Ditchfield et al., 2003). In con-
trast, treatment with the Aurora kinase 
inhibitor ZM447439 induced a much 
milder phenotype: the drug blocked 
paclitaxel-induced mitotic arrest but 
had no effect on nocodazole-induced 
arrest or kinetochore-microtubule 
interactions (Ditchfield et al., 2003). 
Aurora B binds to the proteins Sur-
vivin and INCENP at the centromere, 
and this complex is required for cor-
rect execution of mitosis, suggesting 
that disruption of this complex may 
underlie the more severe phenotype 
resulting from RNAi against Aurora B. 
Indeed, imaging experiments revealed 
that Survivin was absent from centro-
meres after treatment with Aurora B 
RNAi but was localized correctly after 
treatment with ZM447439 (Ditchfield 
et al., 2003). Thus, it is likely that the 
more dramatic phenotype caused by 
Aurora B kinase RNAi is due to loss 
of the scaffolding function of this 
kinase.
In other cases, disruption of a pro-
tein complex can trigger mechanisms 
of cellular compensation that mask 
the phenotype induced by knockout of 
a gene. For example, the PI3-kinases 
p110α and p110β transduce signals 
from growth factors such as insulin, 
but it is unclear which growth factor 
signaling pathways are controlled 
by each PI3-kinase isoform. Knock-
out mice lacking p110α or p110β die 
early in development, indicating that 
these kinases are essential and can-
not compensate for each other (Bi 
et al., 2002). Heterozygous deletion 
of either p110α or p110β leads to no 
detectable phenotype, and dele-
tion of p85, the binding partner of 
p110 proteins, causes a paradoxical 
increase in insulin signaling (Brach-
mann et al., 2005). However, knockin 
animals heterozygous for a p110α 
kinase-dead allele have dramatically 
impaired responses to insulin (Fou-
kas et al., 2006), and p110α-selective 
inhibitors cause a similar decrease in 
insulin signaling (Knight et al., 2006). 
Why is it that p110α inhibitors or Cell 128, Fkinase-dead alleles block insulin sig-
naling, whereas animals lacking p110 
or p85 have normal or even enhanced 
insulin sensitivity? Analysis of tissue 
from heterozygous p110 knockout 
animals showed that reduced p110 
expression is accompanied by a par-
allel reduction in p85 (Brachmann et 
al., 2005). Moreover, careful study of 
p85 knockout animals shows that p85 
can function as a negative regulator 
of PI3-kinase signaling. The model 
that emerges from these experiments 
is that PI3-kinase signaling is control-
led by the relative stoichiometry of 
p110 and p85 rather than the absolute 
expression levels of either protein. 
For this reason, heterozygous dele-
tion of p110α results in a compen-
satory decrease in p85 that leaves 
total PI3-kinase activity unchanged. 
In contrast, expression of a p110α 
kinase-dead allele or treatment with 
a p110α inhibitor blocks the activity 
of this kinase while leaving p85 levels 
unperturbed.
Conclusions
There are now many examples 
where different phenotypes emerge 
depending on whether a protein is 
targeted by a small molecule inhibi-
tor or a knockout of the gene (Table 
1). These discrepancies reveal the 
diverse biological functions of a single 
protein. Given that many therapeutics 
are small molecules, these examples 
challenge the general assumption that 
genetics can act as a surrogate for 
pharmacology in identifying protein 
targets for drug development. In the 
foreseeable future, when every gene 
in every model organism has been 
manipulated through genetics, there 
will still remain a significant fraction 
of undiscovered biology awaiting the 
development of the appropriate small 
molecule tools.
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